Peptides and Heparin Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2017 to 2026

Published on : Jan-2018 | List of Tables : 173 | List of Figures : 129 | No. of Pages : 170 | Report Code : FACT378MR | Format : ppt pdf Excel Word

Peptides are amino acids’ short chains connected through peptide bonds. Peptides are molecules that are commonly known as proteins, whose functions are determined on the basis of the amino acid sequence and size. Heparin is known as disaccharide anticoagulant, commonly referred to as blood thinner, which prevents formation of blood clots. Mast cells and basophils in a body produce heparin, which is stored in mast cells and secreted wherever injuries occur.

global peptides and heparin market

Drug Developers Shifting Back to Peptides owing to Mounting Challenges regarding Small Molecules

While the pharmaceutical sector discerned small molecules as the medicinal agents, therapeutic peptides were considered to be niche products. However, with mounting challenges regarding small molecules, drug developers are shifting their concentration back to small amino acid chains. Although peptides have been deemed ineffective for developing drugs, modern peptide drug designs and formulations have been developed for circumventing their weaknesses. For example, original requirement for injecting peptides such as insulin is fading, with more patient-friendly administrations progressively being developed. In addition, the current society that critically judges undesirable effects and environmental impact of the candidate medicines is embracing the safety offered by peptides.

Heparin is being extensively employed as an antitumor and anti-inflammatory agent. The anti-inflammatory characteristic of heparin, which prevents metastatic spreading of tumor cells, is a new research finding among healthcare professionals. The metastatic spreading of tumor cells is restricted by heparin through neutralization of cationic mediators, inhibition of heparanase, and adhesion molecules. Recent discoveries have meant that heparin is capable of targeting L- and P-selectin & integrin activity, as well as preventing cancer progression.

A new report by Fact.MR projects the global peptide and heparin market to reflect an impressive expansion during the forecast period, 2017 to 2026. Revenues from the market are estimated to exceed US$ 34,000 Mn by 2026-end.

Market Taxonomy

Region

Product Type

Route of Administration

Indication

Distribution Channel

North America

Sodium Heparin

Intravenous

Diabetes

Hospital Pharmacies

Latin America

Ammonium Heparin

Oral Route

Cardiovascular

Retail Pharmacies

Europe

lithium Heparin

Others

Cancer

Online Pharmacies

Japan

Icatibant

 

Metabolic Disorder

 

APEJ

Bivalirudin

 

Central Nervous Systems

 

MEA

Liraglutide

 

Other Indications

 
 

Exenatide

     
 

Goserelin

     
 

Bortezomib

     
 

Other Product Types

     

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

APEJ to Remain Most Remunerative Market for Peptide and Heparin

There has been a growing demand for new oral anticoagulants having better efficacy and safety profiles in Asia-Pacific excluding Japan (APEJ). Side effects related to heparin products, including complications of bleeding and heparin-induced thrombocytopenia has resulted into robust adoption of oral anticoagulants in the region. In addition, rising incidence of cancer, metabolic disorders, and hepatitis, along with advancements in peptide synthesis technology and rapid demand for various peptide therapies in the region are expected to drive the growth in APEJ. APEJ will remain the most remunerative market for peptide and heparin.

Liraglutide and ammonium heparin are expected to remain fast-expanding products in the market. In addition, sales of exenatide, lithium heparin, and sodium heparin will register a similar CAGR through 2026.

Key Research Findings from Fact.MR’s Report on Peptide and Heparin Market

  • Oral route of administration will remain preferred for peptide and heparin
  • Cancer will continue to be the dominant indication segment in the market, in terms of revenues
  • Hospital pharmacies will remain the most lucrative distribution channel for peptide and heparin

Competition Tracking

The global market for peptide and heparin is high fragmented and competitive owing to the presence of a large number of international and regional vendors. These vendors are continuously focusing on the development of generic formulations related to blood coagulation and several other novel therapeutic areas. Companies having the capability of manufacturing drugs for effective treatment of coagulation disorders, along with high efficacy and safety profiles are likely to gain maximum market shares in the foreseeable future. Key market participants identified by the report include Baxter, Celsus, Biofer S.p.A,, Hemmo Pharma, AmbioPharm, Inc., Wockhardt Ltd., Sun Pharmaceutical Industries Ltd., Bachem, Abbott Laboratories, Pfizer Inc., Aspen, Leo Pharma, Teva, Takeda, Sanofi, Novo Nordisk, and Eli Lilly.

NoteThe insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Growth of the global peptide and heparin market is expected to remain affected by key factors such as rising prevalence of chronic ailments, alleviated demand for effective drugs & technology, new product developments, and rising investments by leading market players in R&D activities. This Fact.MR report analyzes the expansion of global peptide and heparin market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.

Scope

The scope of Fact.MR’s report is to analyze the global peptide and heparin market for the forecast period 2017-2022 and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global peptide and heparin market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to peptide and heparin.

Summary

The report commences with a brief information of the global peptide and heparin market. This executive summary sets the tone for the rest of the report, providing users the scope of the report. The executive summary includes important facts and statistics on the global peptide and heparin market.

Overview

The next section offers an overview of the global peptide and heparin market. This comprises an introduction to the market, along with a standard definition of the product – peptide and heparin. In this section, market value and year-over-year growth is offered to the readers. Year-over-year growth provides readers with a broader view of growth patterns over the forecast period.

The report’s succeeding section focuses on drivers, restraints and key trends from macroeconomic, demand, and supply perspectives. Impact analysis of weighted average model-based growth drivers is contained in the report for better provision of decision-making insights to clients.

In order to offer readers with up-to-date information about the latest advancements in the global peptide and heparin market, the report provides updates about market opportunities, which can benefit leading manufacturers of peptide and heparin. With continuous evolution of the healthcare sector, keeping a record of latest developments and trends is fundamental for peptide and heparin manufacturers to formulate key business strategies. Detailed insights about raw material sourcing, supply chain, regulatory approvals, pricing analysis, list of distributors, and cost structure are provided in this section.

The Fact.MR report provides segment-wise analysis and forecast for covering the wide scope of global peptide and heparin market. Key segments that define growth of the global peptide and heparin market include product type, route of administration, indication, distribution channel, and region. In this segmentation analysis, a detailed country-wise forecast across all key market parameters is also included.

The report’s last section comprises of the global peptide and heparin market competitive landscape, to provide readers with the dashboard view of company analysis and market players. This competitive intelligence is based on the providers’ categories across value chain, and their presence in the global peptide and heparin market.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

1. Global Economic Outlook

2. Global Peptide and Heparin Market - Executive Summary

3. Global Peptide and Heparin Market Overview
3.1. Introduction
       3.1.1. Global Peptide and Heparin Market Taxonomy
       3.1.2. Global Peptide and Heparin Market Definition
3.2. Global Peptide and Heparin Market Size (US$ Mn) and Forecast, 2012-2026
       3.2.1. Global Peptide and Heparin Market Y-o-Y Growth
3.3. Global Peptide and Heparin Market Dynamics
3.4. Supply Chain
3.5. Cost Structure
3.6. PESTLE Analysis
3.7. Product Lifecycle
3.8. List of Distributors
3.9. Key Participants Market Presence (Intensity Map) By Region

4. Global Peptide and Heparin Market Analysis and Forecast 2012-2026 
4.1. Global Peptide and Heparin Market Size and Forecast By Product Type , 2012-2026
       4.1.1. Sodium Heparin Market Size and Forecast, 2012-2026
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Ammonium Heparin Market Size and Forecast, 2012-2026
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                4.1.2.2. Market Share Comparison, By Region
                4.1.2.3. Y-o-Y growth Comparison, By Region
       4.1.3. lithium Heparin Market Size and Forecast, 2012-2026
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                4.1.3.2. Market Share Comparison, By Region
                4.1.3.3. Y-o-Y growth Comparison, By Region
       4.1.4. Icatibant Market Size and Forecast, 2012-2026
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region
                4.1.4.2. Market Share Comparison, By Region
                4.1.4.3. Y-o-Y growth Comparison, By Region
       4.1.5. Bivalirudin Market Size and Forecast, 2012-2026
                4.1.5.1. Revenue (US$ Mn) Comparison, By Region
                4.1.5.2. Market Share Comparison, By Region
                4.1.5.3. Y-o-Y growth Comparison, By Region
       4.1.6. Liraglutide Market Size and Forecast, 2012-2026
                4.1.6.1. Revenue (US$ Mn) Comparison, By Region
                4.1.6.2. Market Share Comparison, By Region
                4.1.6.3. Y-o-Y growth Comparison, By Region
       4.1.7. Exenatide Market Size and Forecast, 2012-2026
                4.1.7.1. Revenue (US$ Mn) Comparison, By Region
                4.1.7.2. Market Share Comparison, By Region
                4.1.7.3. Y-o-Y growth Comparison, By Region
       4.1.8. Goserelin Market Size and Forecast, 2012-2026
                4.1.8.1. Revenue (US$ Mn) Comparison, By Region
                4.1.8.2. Market Share Comparison, By Region
                4.1.8.3. Y-o-Y growth Comparison, By Region
       4.1.9. Bortezomib Market Size and Forecast, 2012-2026
                4.1.9.1. Revenue (US$ Mn) Comparison, By Region
                4.1.9.2. Market Share Comparison, By Region
                4.1.9.3. Y-o-Y growth Comparison, By Region
       4.1.10. Other Product Types Market Size and Forecast, 2012-2026
                4.1.10.1. Revenue (US$ Mn) Comparison, By Region
                4.1.10.2. Market Share Comparison, By Region
                4.1.10.3. Y-o-Y growth Comparison, By Region
4.2. Global Peptide and Heparin Market Size and Forecast By Route of Administration , 2012-2026
       4.2.1. Intravenous Market Size and Forecast, 2012-2026
                4.2.1.1. Revenue (US$ Mn) Comparison, By Region
                4.2.1.2. Market Share Comparison, By Region
                4.2.1.3. Y-o-Y growth Comparison, By Region
       4.2.2. Oral Route Market Size and Forecast, 2012-2026
                4.2.2.1. Revenue (US$ Mn) Comparison, By Region
                4.2.2.2. Market Share Comparison, By Region
                4.2.2.3. Y-o-Y growth Comparison, By Region
       4.2.3. Others Market Size and Forecast, 2012-2026
                4.2.3.1. Revenue (US$ Mn) Comparison, By Region
                4.2.3.2. Market Share Comparison, By Region
                4.2.3.3. Y-o-Y growth Comparison, By Region
4.3. Global Peptide and Heparin Market Size and Forecast By Indication, 2012-2026
       4.3.1. Diabetes Market Size and Forecast, 2012-2026
                4.3.1.1. Revenue (US$ Mn) Comparison, By Region
                4.3.1.2. Market Share Comparison, By Region
                4.3.1.3. Y-o-Y growth Comparison, By Region
       4.3.2. Cardiovascular Market Size and Forecast, 2012-2026
                4.3.2.1. Revenue (US$ Mn) Comparison, By Region
                4.3.2.2. Market Share Comparison, By Region
                4.3.2.3. Y-o-Y growth Comparison, By Region
       4.3.3. Cancer Market Size and Forecast, 2012-2026
                4.3.3.1. Revenue (US$ Mn) Comparison, By Region
                4.3.3.2. Market Share Comparison, By Region
                4.3.3.3. Y-o-Y growth Comparison, By Region
       4.3.4. Metabolic Disorder Market Size and Forecast, 2012-2026
                4.3.4.1. Revenue (US$ Mn) Comparison, By Region
                4.3.4.2. Market Share Comparison, By Region
                4.3.4.3. Y-o-Y growth Comparison, By Region
       4.3.5. Central Nervous Systems Market Size and Forecast, 2012-2026
                4.3.5.1. Revenue (US$ Mn) Comparison, By Region
                4.3.5.2. Market Share Comparison, By Region
                4.3.5.3. Y-o-Y growth Comparison, By Region
       4.3.6. Other Indications Market Size and Forecast, 2012-2026
                4.3.6.1. Revenue (US$ Mn) Comparison, By Region
                4.3.6.2. Market Share Comparison, By Region
                4.3.6.3. Y-o-Y growth Comparison, By Region
4.4. Global Peptide and Heparin Market Size and Forecast By Distribution Channel, 2012-2026
       4.4.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
                4.4.1.1. Revenue (US$ Mn) Comparison, By Region
                4.4.1.2. Market Share Comparison, By Region
                4.4.1.3. Y-o-Y growth Comparison, By Region
       4.4.2. Retail Pharmacies Market Size and Forecast, 2012-2026
                4.4.2.1. Revenue (US$ Mn) Comparison, By Region
                4.4.2.2. Market Share Comparison, By Region
                4.4.2.3. Y-o-Y growth Comparison, By Region
       4.4.3. Online Pharmacies Market Size and Forecast, 2012-2026
                4.4.3.1. Revenue (US$ Mn) Comparison, By Region
                4.4.3.2. Market Share Comparison, By Region
                4.4.3.3. Y-o-Y growth Comparison, By Region

5. North America Peptide and Heparin Market Size and Forecast, 2012-2026
5.1. North America Outlook 
5.2. North America Parent Market Outlook 
5.3. North America Target Market Outlook 
5.4. Revenue (US$ Mn) Comparison, By Country 
       5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
       5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
5.5. Revenue (US$ Mn) Comparison, By Product Type 
5.6. Revenue (US$ Mn) Comparison, By Route of Administration 
5.7. Revenue (US$ Mn) Comparison, By Indication 
5.8. Revenue (US$ Mn) Comparison, By Distribution Channel

6. Latin America Peptide and Heparin Market Size and Forecast, 2012-2026
6.1. Latin America Outlook 
6.2. Latin America Parent Market Outlook 
6.3. Latin America Target Market Outlook 
6.4. Revenue (US$ Mn) Comparison, By Country 
       6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
       6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
       6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
6.5. Revenue (US$ Mn) Comparison, By Product Type 
6.6. Revenue (US$ Mn) Comparison, By Route of Administration 
6.7. Revenue (US$ Mn) Comparison, By Indication 
6.8. Revenue (US$ Mn) Comparison, By Distribution Channel

7. Europe Peptide and Heparin Market Size and Forecast, 2012-2026
7.1. Europe Outlook 
7.2. Europe Parent Market Outlook 
7.3. Europe Target Market Outlook 
7.4. Revenue (US$ Mn) Comparison, By Country 
       7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
       7.4.2. UK Market Size and Forecast (US$ Mn), 2012-2026
       7.4.3. France Market Size and Forecast (US$ Mn), 2012-2026
       7.4.4. Spain Market Size and Forecast (US$ Mn), 2012-2026
       7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
       7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
7.5. Revenue (US$ Mn) Comparison, By Product Type 
7.6. Revenue (US$ Mn) Comparison, By Route of Administration 
7.7. Revenue (US$ Mn) Comparison, By Indication 
7.8. Revenue (US$ Mn) Comparison, By Distribution Channel

8. Japan Peptide and Heparin Market Size and Forecast, 2012-2026
8.1. Japan Outlook 
8.2. Japan Parent Market Outlook 
8.3. Japan Target Market Outlook 
8.4. Revenue (US$ Mn) Comparison, By Country 
       8.4.1. Japan Market Size and Forecast (US$ Mn), 2012-2026
8.5. Revenue (US$ Mn) Comparison, By Product Type 
8.6. Revenue (US$ Mn) Comparison, By Route of Administration 
8.7. Revenue (US$ Mn) Comparison, By Indication 
8.8. Revenue (US$ Mn) Comparison, By Distribution Channel

9. APEJ Peptide and Heparin Market Size and Forecast, 2012-2026
9.1. APEJ Outlook 
9.2. APEJ Parent Market Outlook 
9.3. APEJ Target Market Outlook 
9.4. Revenue (US$ Mn) Comparison, By Country 
       9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
       9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
       9.4.3. Indonesia Market Size and Forecast (US$ Mn), 2012-2026
       9.4.4. South Korea Market Size and Forecast (US$ Mn), 2012-2026
       9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
       9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
9.5. Revenue (US$ Mn) Comparison, By Product Type 
9.6. Revenue (US$ Mn) Comparison, By Route of Administration 
9.7. Revenue (US$ Mn) Comparison, By Indication 
9.8. Revenue (US$ Mn) Comparison, By Distribution Channel

10. MEA Peptide and Heparin Market Size and Forecast, 2012-2026
10.1. MEA Outlook 
10.2. MEA Parent Market Outlook 
10.3. MEA Target Market Outlook 
10.4. Revenue (US$ Mn) Comparison, By Country 
       10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
       10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
       10.4.3. Turkey Market Size and Forecast (US$ Mn), 2012-2026
       10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
10.5. Revenue (US$ Mn) Comparison, By Product Type 
10.6. Revenue (US$ Mn) Comparison, By Route of Administration 
10.7. Revenue (US$ Mn) Comparison, By Indication 
10.8. Revenue (US$ Mn) Comparison, By Distribution Channel

11. Global Peptide and Heparin Market Company Share, Competition Landscape and Company Profiles
11.1. Company Share Analysis
11.2. Competition Landscape
11.3. Company Profiles
       11.3.1. Eli Lilly
       11.3.2. Novo Nordisk
       11.3.3. Sanofi
       11.3.4. Takeda
       11.3.5. Teva
       11.3.6. Leo Pharma
       11.3.7. Aspen
       11.3.8. Pfizer Inc.
       11.3.9. Abbott Laboratories
       11.3.10. Bachem
       11.3.11. Sun Pharmaceutical Industries Ltd
       11.3.12. Wockhardt Ltd.
       11.3.13. AmbioPharm, Inc
       11.3.14. Hemmo Pharma
       11.3.15. Biofer S.p.A
       11.3.18. Other Key Players

12. Research Methodology

13. Disclaimer

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Peptides and Heparin Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2017 to 2026